Docket Number:12A-1040313
Inventor:Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
IP Status:TW I644667、US 10548861 B2
Abstract:
The present invention provides a method of using a novel water-soluble antitumor for treatment of cancer including various types of human leukemia, small lung cell carcinoma (SCLC), lymphomas, sarcomas, and others. It revealed that this agent displays potent therapeutic efficacy against various leukemia [such as Acute Myeloid Leukemia (ALL) and Acute B Lymphoblastic leukemia (B-ALL)], lymophomas, small lung cell carcinoma (SCLC), and sarcomas in tumor xenograft and orthotopic models. The early preclinical studies showed that this agent lacks of significant toxicity against non-malignant tissues, hematopoietic cells and hematologic parameters in the drug-treated mice. The present studies indicate that this agent has high potential for further development as a useful antitumor agent for clinical application.
Fields of Application:
The novel antitumor agent can be used as an anticancer agent for the treatment of leukemias, lymphomas, small cell lung cancers, sarcomas, and others.
Advantages when compared to the existing technologies:
We demonstrated that the antitumor agent has a broad spectrum of antitumor activity and is not significant cross-resistance to either Taxol or Vinblastine. In the present invention, we further showed that this agent lacks of toxicity on normal epithelium cells, bone marrow mesenchymal stroma (huMSC), and normal cord blood hematopoietic progenitor cells [colony-forming cells (CFC)], but has higher cytotoxicity against the leukemias than other anticancer drugs such as the alkylating drugs 4-HC, bendamustine, cisplatin, etoposide, SN38, the HSP90 inhibitor PU-H71, doxorubicin, and vincristine, due primarily to their toxicity to normal CFC. Notably, this agent is effectively inhibited human primary pediatric AML and B-ALL transplanted in SNG mice; tumor regression was observed. We also demonstrated that this agent is more potent than topotechan and etoposide in nude mice bearing small cell lung cancer (SCLC) in tumor xenograft models. In addition, we have evaluated the antitumor activity of this agent against the cell growth of various lymphoma and sarcoma cell lines in vitro. We also measured the therapeutic window (TW) of this agent and compared that with alkylating drugs and other chemotherapeutic agents on various human Mantle Cell Lymphoma (MCL) cell lines. The result showed that this agent has the best TW of all the drugs screened when normal hematopoietic cell toxicity is used as a determinant of potential dose limiting toxicity.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
